You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
Trading
Institutions
Fees
Promotions
FAQ
Education
Download
About us
Hong Kong
uSMART
EN
Login/Register
Market News

Market News

HomeMarket NewsDetails

邁博藥業(02181.HK)治療哮喘新藥上市註冊申請獲批

阿思達克 05-24 00:30
邁博藥業－Ｂ(02181.HK)公布，公司核心產品之一CMAB007的上市註冊申請獲中國國家藥藍局批准，用於治療確診為免疫球蛋白E介導的哮喘患者，為內地首個獲國家藥監局批准的國產過敏性哮喘治療性抗體新藥。
邁博藥業-B(02181.HK)
Relevant Stocks
邁博藥業-B(02181.HK)
Business Collaboration
Account Opening

Services

FeesFAQExclusive Trading Tools

About Us

OverviewContact UsMedia Center

Agreement Statement

DisclaimerPrivacy Statement
Contact Us
Customer Service Hotline︰+852 3018 4526
Email︰cs@usmarthk.com
Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong
WhatsApp︰+852 5989 2641
Join the Community：
uSMART-Facebook-Page
uSmart Securities Limited
is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Copyright © 2022 uSMART . All Rights Reserved.